Augurex Abstract Receives ADLM Immunology Abstract Award and Selected for Highlighted ePoster Discussion at ADLM 2026
Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, today announced that its scientific abstract, "Anti-14-3-3eta Autoantibodies: A Novel Diagnostic Biomarker that Discriminates Axial Spondyloarthritis from Mechanical Back Pain," has been selected to receive the Immunology Abstract Award at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Conference.
The award, presented by ADLM's Immunology & Infectious Disease (IID) Division, recognizes outstanding scientific contributions in immunology and infectious disease. The abstract was selected from approximately 800 scientific abstracts submitted for presentation at the ADLM 2026 Conference.
In addition to receiving the Immunology Abstract Award, the abstract has been selected for presentation during an IID Division ePoster Discussion, a featured scientific session highlighting top-rated abstracts within the discipline. ePoster Discussions provide attendees with an opportunity to engage with emerging research and discuss findings that have the potential to influence future clinical practice and laboratory medicine.
